Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Preveceutical Medical Inc C.PREV

Alternate Symbol(s):  PRVCF

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its Non-Addictive Analgesic is an engineering non-addictive analgesic peptide for pain management. Its Dual Gene Therapy targets type 2 diabetes and obesity. The Company’s subsidiary, PreveCeutical (Australia) Pty Ltd., manages its research programs.


CSE:PREV - Post by User

Preveceutical Medical Inc > From Dean (redacted)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by MrAwesome1979on Jul 29, 2020 12:11pm
224 Views
Post# 31337685

RE:From Dean (redacted)

RE:From Dean (redacted)
MrAwesome1979 wrote: Thanks for your inquiry Financials are due on or before Aug 29 I cant comment on when next news is coming we are bidding on some active tenders (no award yet) As far as marketing / promo are you referring to the stock or for products? Dean (Follow up answers) At this time I am the only one employed in any capacity related to the stock. I am aware of a number of programs / campaigns that other companies use to generate enthusiasm / hype but I dont use them. We have used some digital marketing but no paid for promotion. We use theNewswire.com for the distribution / dissemination of news releases. There is no dilution they are a service. We pay an annual fee for unlimited distribution of news releases As far as dilution for other companies they will generally provide shares from an insider / party close to insider to run a promotion. It may create a short term bump but the majority of the time doesnt last. Having been an investor relations consultant for the last 20 years after working with a regulatory body I have witnessed a number of promotions but dont engage in these activities. I dont anticipate that TTD will engage a promotional company No problem with the questions id be asking as well Thx Dean Stuart Boardmarker Group T: 403 617 7609 E:dean@boardmarker.net W:www.boardmarker.net Twitter: @tsxir


WRONG BOARD SORRY
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities